{"id":"https://openalex.org/W2037201632","doi":"https://doi.org/10.1097/cmr.0000000000000014","title":"Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium","display_name":"Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium","alternate_titles":[],"publication_year":2013,"publication_date":"2013-08-22","ids":{"openalex":"https://openalex.org/W2037201632","doi":"https://doi.org/10.1097/cmr.0000000000000014","mag":"2037201632","pmid":"https://pubmed.ncbi.nlm.nih.gov/23969699"},"language":"en","primary_location":{"id":"doi:10.1097/cmr.0000000000000014","doi":"https://doi.org/10.1097/cmr.0000000000000014","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000014","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2037201632"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5035148529","display_name":"Ralph J. Hauke","orcid":"https://orcid.org/0000-0002-0243-7279","observed_orcids":["https://orcid.org/0000-0002-0243-7279"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210153252","display_name":"Nebraska Cancer Specialists","ror":"https://ror.org/052z1v370","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153252"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ralph J. Hauke","raw_affiliation_strings":["aNebraska Cancer Specialists, Omaha, Nebraska bSarah Cannon Research Institute cTennessee Oncology, PLLC, Nashville, Tennessee dFlorida Cancer Specialists, Fort Myers, Florida, USA","Nebraska Cancer Specialists, Omaha, Nebraska"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"aNebraska Cancer Specialists, Omaha, Nebraska bSarah Cannon Research Institute cTennessee Oncology, PLLC, Nashville, Tennessee dFlorida Cancer Specialists, Fort Myers, Florida, USA","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210153252"]},{"raw_affiliation_string":"Nebraska Cancer Specialists, Omaha, Nebraska","institution_ids":["https://openalex.org/I4210153252"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103514741","display_name":"Jeffrey R. Infante","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Jeffrey R. Infante","raw_affiliation_strings":["Sarah Cannon Research Institute","Tennessee Oncology, PLLC, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute","institution_ids":["https://openalex.org/I172427033"]},{"raw_affiliation_string":"Tennessee Oncology, PLLC, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103466743","display_name":"Mark S. Rubin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mark S. Rubin","raw_affiliation_strings":["Florida Cancer Specialists, Fort Myers, Florida, USA","Sarah Cannon Research Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Cancer Specialists, Fort Myers, Florida, USA","institution_ids":[]},{"raw_affiliation_string":"Sarah Cannon Research Institute","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101919113","display_name":"Kent C. Shih","orcid":"https://orcid.org/0000-0002-6718-6116","observed_orcids":["https://orcid.org/0000-0002-6718-6116"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Kent C. Shih","raw_affiliation_strings":["Sarah Cannon Research Institute","Tennessee Oncology, PLLC, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute","institution_ids":["https://openalex.org/I172427033"]},{"raw_affiliation_string":"Tennessee Oncology, PLLC, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113722082","display_name":"Edward R. Arrowsmith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Edward R. Arrowsmith","raw_affiliation_strings":["Sarah Cannon Research Institute","Tennessee Oncology, PLLC, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute","institution_ids":["https://openalex.org/I172427033"]},{"raw_affiliation_string":"Tennessee Oncology, PLLC, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065917441","display_name":"John Daniel Hainsworth","orcid":"https://orcid.org/0000-0002-2848-6546","observed_orcids":["https://orcid.org/0000-0002-2848-6546"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]},{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["GB","US"],"is_corresponding":true,"raw_author_name":"John D. Hainsworth","raw_affiliation_strings":["Sarah Cannon Research Institute","Tennessee Oncology, PLLC, Nashville, Tennessee","to John D. Hainsworth, MD, Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA Tel: +1 615 329 7274; fax: +1 615 340 1539; e-mail: [email\u00a0protected]","e-mail: [email\u00a0protected]","fax: +1 615 340 1539","to John D. Hainsworth, MD, Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA Tel: +1 615 329 7274"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute","institution_ids":["https://openalex.org/I172427033"]},{"raw_affiliation_string":"Tennessee Oncology, PLLC, Nashville, Tennessee","institution_ids":["https://openalex.org/I4210135086"]},{"raw_affiliation_string":"to John D. Hainsworth, MD, Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA Tel: +1 615 329 7274; fax: +1 615 340 1539; e-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4210100810"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +1 615 340 1539","institution_ids":[]},{"raw_affiliation_string":"to John D. Hainsworth, MD, Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA Tel: +1 615 329 7274","institution_ids":["https://openalex.org/I4210100810"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5065917441"],"corresponding_institution_ids":["https://openalex.org/I172427033","https://openalex.org/I4210100810","https://openalex.org/I4210135086"],"apc_list":null,"apc_paid":null,"fwci":1.2714,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":{"value":0.7798826,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"23","issue":"6","first_page":"468","last_page":"473"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.7314000129699707,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.7314000129699707,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.21809999644756317,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.031199999153614044,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/everolimus","display_name":"everolimus","score":0.9929999709129333},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9990000128746033},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":1.0},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/first-line-chemotherapy","display_name":"first-line chemotherapy","score":0.6439999938011169},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6890000104904175},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.7110000252723694},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7649999856948853},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.9390000104904175},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.6669999957084656}],"concepts":[{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.9382727146148682},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.880785346031189},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.8027081489562988},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.7158747911453247},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.7012291550636292},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5654358267784119},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5547230243682861},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5389682650566101},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5331494212150574},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.38958126306533813},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.32741206884384155},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.11387237906455994}],"mesh":[{"descriptor_ui":"D000068338","descriptor_name":"Everolimus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000096142","descriptor_name":"Cutaneous Malignant Melanoma","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016190","descriptor_name":"Carboplatin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/cmr.0000000000000014","doi":"https://doi.org/10.1097/cmr.0000000000000014","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000014","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},{"id":"pmid:23969699","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23969699","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma research","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":12,"referenced_works":["https://openalex.org/W1979300931","https://openalex.org/W1981342298","https://openalex.org/W2008793220","https://openalex.org/W2016569614","https://openalex.org/W2032870664","https://openalex.org/W2060317877","https://openalex.org/W2065701510","https://openalex.org/W2089168156","https://openalex.org/W2127120957","https://openalex.org/W2167010784","https://openalex.org/W2330814896","https://openalex.org/W3041047318"],"related_works":["https://openalex.org/W2604083871","https://openalex.org/W2765775340","https://openalex.org/W1997452749","https://openalex.org/W2588114225","https://openalex.org/W1981342298","https://openalex.org/W2516486578","https://openalex.org/W1969738419","https://openalex.org/W1978729515","https://openalex.org/W1964505914"],"abstract_inverted_index":{"This":[0],"phase":[1],"II":[2],"trial":[3],"examined":[4],"the":[5,61,121,133,137,145,172],"efficacy":[6,184],"and":[7,15,57,77,85,87],"toxicity":[8,162],"of":[9,83,118,152,159,175,182,195],"first-line":[10,42,173],"treatment":[11,43,70,174],"with":[12,19,24,36,44,187,190],"everolimus,":[13],"paclitaxel,":[14],"carboplatin":[16,58],"in":[17,171],"patients":[18,23,79,99,109,153],"advanced":[20,28,176],"melanoma.":[21],"Seventy":[22],"metastatic":[25],"or":[26,38,95],"locally":[27],"unresectable":[29],"melanoma":[30],"who":[31],"had":[32],"been":[33],"untreated":[34],"previously":[35],"chemotherapy":[37],"targeted":[39],"agents":[40],"received":[41,80],"everolimus":[45,91],"(5":[46],"mg,":[47],"orally,":[48],"daily),":[49],"paclitaxel":[50,84],"(175":[51],"mg/m,":[52],"intravenous,":[53,64],"every":[54,65,73],"3":[55,66],"weeks),":[56],"(area":[59],"under":[60],"curve":[62],"6.0,":[63],"weeks).":[67],"Response":[68],"to":[69],"was":[71,125,140,144,169,179],"assessed":[72],"6":[74],"weeks;":[75],"responding":[76],"stable":[78],"six":[81],"cycles":[82],"carboplatin,":[86],"subsequently":[88],"continued":[89],"single-agent":[90],"until":[92],"disease":[93],"progression":[94],"unacceptable":[96],"toxicity.":[97],"Twelve":[98],"(17%)":[100],"showed":[101,110],"objective":[102],"responses":[103],"(all":[104],"partial);":[105],"an":[106],"additional":[107],"27":[108],"measurable":[111],"tumor":[112],"shrinkage.":[113],"After":[114],"a":[115],"median":[116,122,134],"follow-up":[117],"15":[119],"months,":[120],"progression-free":[123],"survival":[124,135],"4.0":[126],"months":[127],"(95%":[128],"confidence":[129],"interval":[130],"2.8-5.0":[131],"months);":[132],"for":[136],"entire":[138],"group":[139],"10.1":[141],"months.":[142],"Myelosuppression":[143],"most":[146],"common":[147],"grade":[148,160],"3/4":[149,161],"toxicity;":[150],"70%":[151],"experienced":[154],"at":[155],"least":[156],"one":[157],"episode":[158],"while":[163],"on":[164],"study.":[165],"Although":[166],"this":[167,196],"regimen":[168],"active":[170],"melanoma,":[177],"there":[178],"no":[180],"suggestion":[181],"improved":[183],"when":[185],"compared":[186],"previous":[188],"results":[189],"paclitaxel/carboplatin":[191],"alone.":[192],"Further":[193],"study":[194],"combination":[197],"is":[198],"not":[199],"recommended.":[200]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2037201632","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}
